The government is going to assess efficacy data of all concerned companies (working on COVID-19 vaccines) before inking a purchase contract with them and will buy vaccines at least for essential workers

India Stock Market News Updates Today: IndusInd Bank, M&M, TCS, Bajaj Finance, Bharti Airtel, Sun Pharma, Maruti, Tata Steel and Axis Bank were among the top gainers on Sensex pack. Kotak Bank wa the only loser.

India Stock Market Highlights Today: All Sensex components were in the red with M&M, Bajaj Finance, IndusInd Bank, Maruti, Axis Bank, Bajaj Finserv and ICICI Bank shedding up to 33%.

Gagandeep Kang, professor of microbiology at Christian Medical College said that by year-end, data on which vaccine candidate is working and which not will be made available

A vaccine is definitely needed to control the spread of this disease, but the vaccine alone is not enough, and other efforts such as social distancing, wearing mask, isolating and testing people will continue to remain important

Addressing the Rajya Sabha over the coronavirus situation in the country, Dr. Harsh Vardhan said that India is also making efforts like other nations, adding that \"three vaccine candidates are in different phases\" of clinical trials

COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief

Union Health Minister Harsh Vardhan on Sunday said that he will be the first person to take COVID-19 vaccine so as to dispel the \"trust deficit\" around the same

Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus

Dr VK Paul informed the Russian government has approached India to facilitate the Phase-3 trial of their vaccine and also manufacture Sputnik V through Indian companies

WHO's recommendation is based on three new studies, plus four other earlier trials, all involving a drug from the family of corticosteroids

Initially, the ICMR vaccine portal will disseminate information on coronavirus vaccine in India. However, with time, data available for all the vaccines will be added to the portal

Last month, the medical journal Lancet wrote that the Phase-2 clinical trial of CanSino Biologics' adenovirus vector vaccine or Ad5-nCoV was safe and induced immune response

Independence day: 'Today, in India, not one or two but three vaccines are in the stage of testing. As soon as there is a green signal from scientists, the country is prepared to produce it in large numbers,' PM Modi said

Coronavirus vaccine news update: India's own research institution, the Indian Council of Medical Research (ICMR) is on record for its push to cut down red tapism and accelerate the development of COVID-19 vaccines

The drug discovery pipeline is a type of computational strategy linked to AI -- a computer algorithm that learns to predict activity through trial and error, improving over time

Remdesivir price: Zydus is the fifth Indian company to launch the drug for coronavirus treatment after Hetero Labs, Cipla, Mylan NV and Jubilant Life Sciences. Priced at Rs 2,800 for a 100 mg lyophilized injection, its brand 'Remdac' will be the most economical

Zydus has priced it at 2,800 rupees ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients

The committee members will take the decision on vaccines that will be effective for Indian citizens. The task force will also chalk out a budget and discuss how capital can be raised for procurement, distribution of the vaccine

The task force will also chalk out a budget and discuss how capital can be raised for procurement, distribution of the vaccine